An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions 

Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights 

Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients 

IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy? 

The role of neoadjuvant versus adjuvant immunotherapy is no simple comparison but instead involves a complex interplay of factors, based on tumour immune responsiveness, immunotherapy type, combination partners and trial design

In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment 

Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine 

Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility 

Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments

After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types